Your browser doesn't support javascript.
loading
Ocular findings in patients with histiocytosis and association with clinical and molecular features.
Francis, Jasmine H; Reiner, Anne S; Canestraro, Julia; Rampal, Raajit K; Abramson, David H; Diamond, Eli L.
Afiliación
  • Francis JH; Ophthalmic Oncology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA francij1@mskcc.org.
  • Reiner AS; Weill-Cornell Medical Center, New York, New York, USA.
  • Canestraro J; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Rampal RK; Ophthalmic Oncology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Abramson DH; Weill-Cornell Medical Center, New York, New York, USA.
  • Diamond EL; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Br J Ophthalmol ; 2024 May 24.
Article en En | MEDLINE | ID: mdl-38789131
ABSTRACT
BACKGROUND/

AIMS:

Ocular manifestations of histiocytosis and their genetic underpinnings are poorly characterised. This study characterises ocular sites of histiocytosis, notate genetic alterations and correlates to histiocytosis clinical features including subtype and sites of disease.

METHODS:

Prospective registry-based study of predominantly adult histiocytosis patients at a single-institution tertiary referral centre. 180 eyes of 90 patients (46 males, 44 females) with histiocytosis (Erdheim-Chester disease 34, Rosai-Dorfman 20, xanthogranuloma 7, mixed histiocytosis 13, Langerhans cell histiocytosis (LCH) 15, ALK-positive histiocytosis 1). Ocular findings were categorised by the structure involved. Histiocytosis subtype, sites of disease and genetic status were correlated to ocular findings.

RESULTS:

Ocular disease was present in more than half the histiocytosis patient cohort and occurred with other disease sites. Ocular findings were statistically significantly different across histiocytic subtypes with LCH subtypes having the lowest proportion of ocular findings (7%) and all other subtypes having rates of ocular findings which were five times that of patients with LCH (p=0.0009). Of patients with ocular findings, 41% of patients reported ocular symptoms and were significantly more in the group with ocular disease present versus those patients without ocular involvement. The presence of ocular findings was not statistically different by BRAFV600E, MAP2K1 or RAS isoform mutational status.

CONCLUSIONS:

Ocular disease is a common feature of histiocytosis with significant visual symptomatology and occurrence in tandem with multisystem sites. Ocular findings vary by histiocytic subtype. The mutational profile of the cohort reflects known mutations in this clinical population, with no specific driver mutation associated with ocular disease.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Br J Ophthalmol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Br J Ophthalmol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos